China Healthwise Holdings Limited Overview
China Healthwise is a Hong Kong micro-cap investment holding company whose only meaningful operating asset is Nam Pei Hong Sum Yung Drugs Company Limited, a traditional "Sum Yung" (參茸, ginseng and deer-antler tonics) and premium dried-seafood retailer trading under the Nam Pei Hong (南北行) brand since 1977. The Chinese health products segment generated HK$99.2 million of the group's HK$99.6 million FY2025 revenue through nine retail shops, direct sales events, wholesale and online channels including HKTVmall and a Tmall Global flagship. Two adjunct segments — a legacy money-lending book (HK$305.7 million gross, ~97% credit-impaired) and a listed-equity portfolio — have driven most of the group's volatility and cumulative losses of over HK$330 million since FY2021. The company is in capital deficiency (net liabilities HK$50.1 million at 30 June 2026), carries a going-concern material uncertainty, and faces HK$72.3 million of bond principal maturing on 30 December 2026. It is effectively a distressed-balance-sheet situation wrapped around a heritage consumer brand.
Company's own description (FY2024 results announcement / FY2025 annual report)
The Company describes itself as "an investment holding company and principally engaged in investment in financial instruments", with subsidiaries "principally engaged in sale of Chinese health products, money lending business and investment in financial instruments." The Chinese health products business "engaged in the sales of Chinese and other pharmaceutical products, health products, ginseng and dried seafood products to wholesaler and retailer," with Nam Pei Hong Sum Yung Drugs Company Limited trading and retailing Sum Yung and dried seafood products since 1977 under a brand the Company states is "highly recognised in Hong Kong and Southern Mainland China." (Source: FY2024 annual results announcement, 31 March 2025; repeated verbatim in H1 2026 interim results, 27 August 2026.)
Independent characterisation
In substance China Healthwise is three unrelated activities held together by a common controlling-influence shareholder group (Eternity Investment Limited and its nominated directors):
-
A heritage specialty retailer (≈99.6% of FY2025 revenue). Nam Pei Hong sells high-value traditional Chinese tonic products — cordyceps sinensis, Korean and American ginseng, pilose antler, bird's nest, fish maw, sea cucumber, dried scallops, dendrobium — plus a growing range of convenient packaged health foods. It is a merchandising and sourcing business, not a manufacturer: the Company reports no production facilities and no R&D. Gross margin on goods is a stable low-30s percent (derived: 30.7%–34.0% across FY2021–H1 2026). Sales are seasonal, peaking around winter and Chinese New Year.
-
A run-off consumer/commercial money-lending book. The licensed money-lending subsidiary has written no new loans to new customers since FY2023; of eleven loans outstanding at 30 June 2026, nine (HK$296.7 million gross) are stage 3 credit-impaired and fully provided. The live book (HK$9.0 million) is dominated by a revolving facility to the ultimate holding company of the substantial shareholder.
-
A proprietary listed-equity portfolio. Financial assets at fair value through profit or loss fell from HK$54.0 million (31 Dec 2025) to HK$14.1 million (30 Jun 2026) after forced and voluntary disposals; current holdings are Ocean Line Port Development (8502.HK) and Yunfeng Financial (0376.HK). Realised gains/losses on disposals are booked within revenue, which distorts reported top line and gross margin.
Business and revenue model
| Revenue type | Segment | Recognition | FY2025 share of revenue |
|---|---|---|---|
| Product sales (retail, direct-sales events, wholesale, internet) | Chinese health products | Point in time (HKFRS 15) | ≈99.6% |
| Interest income | Money lending | Effective interest (HKFRS 9) | ≈0.6% |
| Dividends and realised gains/losses on disposal of equities | Investment in financial instruments | HKFRS 9 | ≈-0.3% (net realised loss) |
There is no subscription, licensing or service revenue. Value-chain position: downstream importer–wholesaler–retailer, with management emphasising "overseas direct sourcing" to compress procurement cost (FY2024 and H1 2026 MD&A).
Customers and end-markets
| Chinese health products channel (HKD Mn) | FY2021 | FY2022 |
|---|---|---|
| Retail shops | 66.04 | 73.72 |
| Direct sales events | 33.98 | 41.17 |
| Internet | 12.60 | 12.47 |
| Wholesale | 1.58 | 1.01 |
| Total Chinese health products | 114.20 | 128.38 |
Customers are predominantly Hong Kong retail consumers (older, gift-giving and health-conscious households), event-based buyers at expos and festivals, corporate/institutional buyers (charities, banks and insurers via staff-purchase programmes), wholesalers, and online buyers (HKTVmall; Tmall Global for Mainland cross-border). No single customer contributed ≥10% of revenue in any year FY2021–H1 2026. End-markets: Hong Kong traditional Chinese medicine (TCM) and tonic retail, premium dried seafood, functional/health foods.
Sales-channel mix is disclosed only for FY2021–FY2022:
Source: FY2022 annual results announcement, note 3. Later years: not disclosed in results announcements reviewed.
Strategy
Stated strategic themes (FY2024 annual results, H1 2026 interim)
Defend the core retail franchise: under the motto "genuine goods at fair prices, treating all customers honestly", leveraging overseas direct sourcing to keep prices competitive.
Pivot product mix to convenient ready-to-eat health products: for younger consumers, aligned with the national "medicine-food homology" (藥食同源) wellness direction.
Channel diversification: HKTVmall live-streaming, Xiaohongshu storefront with Weimob, corporate staff-purchase programmes with banks and insurers, department-store and supermarket collaborations (Sogo, YATA), OpenRice activities.
Technology and CRM: upgrade membership/CRM system; apply AI in marketing to raise repurchase rates and store revisit frequency.
Cost control: shop-level cost discipline, staff training, G&A reductions.
Money lending: no new lending; recovery via settlement, legal action, collateral enforcement; stricter credit policy.
Investments: adjust portfolio, realise equities into cash "as and when appropriate".
Business portfolio management: "actively looking for business opportunities to diversify the revenue sources" via investments or acquisitions.
Liquidity plan (going-concern note): collect loan receivables; realise FVTPL assets; cost savings; negotiate renewal of bonds and borrowings with the bondholder and finance company.
Initiatives in the last 24 months
| Initiative | Announced | Status at Oct 2026 |
|---|---|---|
| MAME LAB partnership (prenatal/postnatal products) | Mar 2025 | Status not updated in H1 2026 filing |
| Xiaohongshu launch with Weimob | Mar 2025 | Not confirmed as launched |
| CRM membership upgrade | Mar 2025 | In progress |
| Corporate staff-purchase channel expansion | Aug 2026 | Planned |
| AI-assisted marketing | Aug 2026 | Planned |
| 2024 Bond restructuring | Aug–Dec 2024 | Completed 31 Dec 2024; bonds due 30 Dec 2026 |
| New Share Option Scheme | Aug 2024 | Adopted; no grants |
| Equity subscription (HK$10.8 M) | Aug 2026 | Completed 27 Aug 2026 |
| 5:1 share consolidation | Aug 2026 | Effective 22 Sep 2026 |
| Investment policy formalisation | Annual Report 2025 | Adopted |
Medium-term targets and guidance
No quantitative revenue, margin or return targets have been published. The Company does not issue earnings guidance; it issues Listing Rule 13.09 profit alerts (e.g., positive alert for H1 2025). ESG/sustainability targets: not publicly disclosed in the sources reviewed.
Products & Services
Chinese health products segment (brand: Nam Pei Hong 南北行)
| Product / category | Description and use | Target customer | Latest disclosed trend | Source |
|---|---|---|---|---|
| Cordyceps sinensis (冬蟲夏草) | Premium caterpillar-fungus tonic; respiratory and vitality tonic in TCM | Affluent health-conscious, gift buyers | FY2024 sales declined (range 10%–34% across high-end lines) | FY2024 MD&A |
| Wild cordyceps sinensis (野生冬蟲夏草) | Top-grade wild-harvested variant | High-end | H1 2026 growth 4%–16% (group of growth lines) | H1 2026 MD&A |
| Ginseng (人參) — general | Range of ginseng roots/slices | Mass-affluent, elderly | FY2024 decline | FY2024 MD&A |
| Korean ginseng (高麗參) | Red ginseng roots | High-end, gifting | H1 2026 decline (6%–30% range) | H1 2026 MD&A |
| American ginseng (花旗參) | Cooling tonic, slices and whole roots | Mass-affluent | H1 2026 decline | H1 2026 MD&A |
| Pilose antler (鹿茸) | Deer-antler tonic (core "Sum Yung" category) | Older consumers | H1 2026 decline; affected by Mainland customs controls on carrying high-end products | H1 2026 MD&A |
| Dendrobium (石斛) | Orchid-stem yin tonic | Health-conscious | H1 2026 decline | H1 2026 MD&A; FY2022 promotion focus |
| Tianqi (田七) | Notoginseng; circulation tonic | Elderly | Promotion focus FY2022 | FY2022 MD&A |
| Bird's nest (燕窩) | Edible swiftlet nest | Women, gifting | FY2024 decline; H1 2026 growth | FY2024, H1 2026 MD&A |
| Fish maw (花膠) | Dried swim bladder, collagen-rich | Gifting, festive cooking | FY2024 and H1 2026 decline | MD&A |
| Dried scallops (元貝) | Premium dried seafood | Festive cooking | FY2024 decline | FY2024 MD&A |
| Sea cucumber (海參) | Dried sea cucumber | Festive and tonic | FY2024 sales +28%; H1 2026 growth | MD&A |
| Japanese stichopus (日本刺參) | Premium Japanese spiky sea cucumber | High-end | H1 2026 growth | H1 2026 MD&A |
| Tai Chi Ginseng Fruit (太極蔘正果) | Ready-to-eat ginseng confection | Younger / convenience | Promotion focus 2025 | FY2024 MD&A |
| Collagen Jelly (膠原果凍) | Ready-to-eat beauty jelly | Younger women | Promotion focus 2025 | FY2024 MD&A |
| Pure Sea Cucumber Essence Capsules (純海參精華膠囊) | Supplement capsule | Health-conscious | Promotion focus 2025 | FY2024 MD&A |
| Probiotics F+ (益生菌F+) | Probiotic supplement | Convenience | Promotion focus 2025 | FY2024 MD&A |
| Platycodon throat lozenges (桔梗順氣潤喉寶) | Herbal throat lozenge | Mass market | Promotion focus 2025 | FY2024 MD&A |
| Herbal teas / health flower teas (養生保健花茶) | Packaged teas | Mass market | Stable sales H1 2026 | MD&A |
| Canned Premium Goji Berries (特級貢杞皇) | Packaged dried goji | Convenience | Stable H1 2026 | H1 2026 MD&A |
| Premium Peach Gum (特級桃膠) | Packaged dessert/beauty ingredient | Convenience | Stable H1 2026 | H1 2026 MD&A |
| Premium Snow Lotus Seed (特級雪蓮子) | Packaged dessert ingredient | Convenience | Stable H1 2026 | H1 2026 MD&A |
| Ginseng powder, energy drink, probiotics capsules, ganoderma capsules | Convenience health products | Busy urban consumers | Listed FY2022 | FY2022 MD&A |
| Anti-epidemic tea bags, nutrition stew series, gift hampers | Corporate/institutional orders | Charities, institutions | FY2022 | FY2022 MD&A |
| Seasonal health product portfolios | Seasonal bundles and promotions | All | Ongoing | FY2024 MD&A |
| Prenatal/postnatal maternal health products (planned) | Via MAME LAB postpartum-care centre partnership | Mothers | Announced plan 2025 | FY2024 MD&A |
Pricing is not publicly disclosed in filings; all products are retail-priced per weight/grade or per package.
Channels and platforms
| Channel | Detail | Status |
|---|---|---|
| Nam Pei Hong retail shops | 10 (end-2021 to end-2024) → 9 (end-2025 and 30 Jun 2026); locations not itemised in announcements | Operating; loss-making shops impaired |
| Direct-sales events | Brands and Products Expo (工展會), food festivals, large-scale shopping events; Sogo and YATA VIP Days | Operating |
| HKTVmall | Online marketplace sales and live-streaming | Operating; FY2022 HKTVmall turnover +20% |
| Tmall Global "Nam Pei Hong Overseas Flagship Shop" | Cross-border e-commerce to Mainland | Launched 2022 |
| Xiaohongshu (小紅書) via Weimob (微盟) | Social-commerce storefront | Announced as forthcoming (FY2024 results); launch not confirmed in later filings |
| OpenRice platform activities; Facebook, YouTube shorts | Digital marketing | Operating (H1 2026) |
| Corporate staff-purchase programmes (banks, insurers) | B2B2C channel | Planned expansion (H1 2026) |
| CRM / membership system | Upgrade announced; AI-driven marketing to raise repurchase | In progress |
Money lending segment
Unsecured, fixed-rate loans of 8%–13% p.a. (8%–15% in FY2021–FY2022). No new loans granted to new customers since FY2023. The only active facility is a HK$9.0 million revolving loan to the ultimate holding company of a substantial shareholder (Eternity group), rate revised to 10% fixed from March 2026, maturity March 2027.
Investment in financial instruments segment
Listed equity holdings at 30 June 2026: Ocean Line Port Development Ltd (8502.HK) — 31,588,000 shares, 3.95% stake, fair value HK$9.79 M; Yunfeng Financial Group (0376.HK) — 2,634,000 shares, 0.06%, fair value HK$4.24 M. Previously held Huanxi Media Group (1003.HK; 19.65 M shares, fair value HK$9.14 M at end-2024), disposed during 2025–H1 2026 (exact timing not disclosed). The FY2025 annual report sets an investment policy limiting single investments to 10% of total assets, non-Hong Kong assets to 10% of the portfolio, prohibiting commodity derivatives and day trading, and benchmarking returns against the 12-month HKD time-deposit rate.
Financial Narrative
Income statement: notes and sources
Notes: EBIT = pre-tax income + finance costs (derived). EBITDA = EBIT + depreciation of PPE and right-of-use assets (FY2021 4.20; FY2022 3.30; FY2023 5.62; FY2024 7.17) (derived; IFRS 16 basis, includes lease depreciation). FY2025 EPS derived (HK$2.61 M / 770.48 M shares). FY2025 pre-tax income, tax and other-income total were not available in the sources reviewed; a vendor (MarketInOut) reports FY2025 EBITDA of HK$10.54 M, which is not reconciled to filings and is not used here. Sources: annual results announcements FY2022 (FY2021–22), FY2024 (FY2023–24); FY2025 results summary (Bulletin Express, 27 Mar 2026).
Margins and growth
Revenue CAGR FY2021–FY2025: -12.5% (group, derived); -3.5% (Chinese health products, derived). FY2021 growth uses FY2020 revenue of HK$137.85 M (vendor data).
Commentary. Reported gross margin is not a meaningful operating indicator because realised investment gains and interest income are booked in revenue with no associated cost of sales; the collapse from 53.5% (FY2021) to 33.6% (FY2025) is almost entirely mix — the disappearance of HK$56 M of high-margin financial revenue. The goods-only gross margin has in fact been stable to slightly improving at 31%–34%, reflecting direct overseas sourcing and a mix shift toward sea cucumber and packaged products. The principal profit drivers each year were (i) ECL charges on the loan book (HK$102.6 M FY2021, HK$107.5 M FY2023), (ii) fair-value swings on equities, and (iii) from FY2025, rising finance costs after the 2024 bond restructuring (effective interest 15% p.a. on the bond liability components). Underlying operating expenses have been cut materially: G&A fell 44% from FY2022 to FY2025 (HK$38.3 M → HK$21.6 M), driven by lower directors' emoluments (HK$20.2 M FY2022 → HK$9.1 M FY2024). The FY2025 near-breakeven (HK$2.6 M loss) was flattered by a HK$24.6 M unrealised fair-value gain that partly reversed in H1 2026 (HK$11.7 M realised loss on disposal plus HK$4.7 M fair-value loss).
Balance sheet
Debt composition: FY2021 borrowings 12.04 + 2018 CBs 72.30; FY2022 borrowings 31.26 (current) + CBs 71.04 (non-current); FY2023 borrowings 28.72 + CBs 72.24 (both current); FY2024 borrowings 32.57 (current) + CBs 14.30 + straight bonds 49.00 (non-current); FY2025 borrowings 31.43 + CBs 15.46 + bonds 52.00 (all current). Net debt derived. Source: annual results FY2022, FY2024; H1 2026 interim (31 Dec 2025 comparatives).
Latest interim balance sheet (30 June 2026)
Post-balance-sheet: HK$10.8 M gross subscription proceeds received 27 Aug 2026, earmarked for working capital and repayment of current debt.
Cash flow
Change in cash derived from year-end balances. The Company confirmed no repurchases of its listed securities in FY2022, FY2024 and H1 2026.
Ratios
All derived from reported figures. Blank ROE/D-E cells: equity negative (FY2024–FY2025) or prior-year base unavailable (FY2021). Net debt/EBITDA not meaningful (negative EBITDA). Invested capital = equity + debt + leases − cash.
Commentary. The balance sheet has moved from HK$193 M of equity (FY2021) to a HK$50 M capital deficiency (H1 2026) in 4.5 years. Debt has been essentially flat at ~HK$96–102 M throughout — the problem is the asset side: the loan book that was supposed to service the 2018 CBs defaulted. The restructuring at end-2024 merely re-termed the CB principal into two-year paper now maturing 30 December 2026, and the H1 2026 forced deleveraging of margin loans (HK$15.6 M → HK$2.4 M) was funded by selling equities at a HK$11.7 M realised loss. Inventory days of 220–280 are long but typical for dried tonics with seasonal stocking; the cash conversion cycle has improved through tighter receivables. Interest coverage is negative every year; even the retail operation's segment loss excludes HK$5 M of unallocated bond interest per half-year.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key entity | Status |
|---|---|---|---|
Chinese health products | Retail, direct-sales-event, wholesale and online sale of Sum Yung, dried seafood, Chinese and other pharmaceutical and health products | Nam Pei Hong Sum Yung Drugs Company Limited | Core, operating |
Money lending business | Unsecured fixed-rate loans (8%–13% p.a.) under Hong Kong Money Lenders Ordinance licence | Money-lending subsidiary (name not disclosed in announcements reviewed) | Run-off / recovery |
Investment in financial instruments | Proprietary investment in Hong Kong listed (and minor unlisted) equities | Investment subsidiaries | Shrinking; used as liquidity source |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese health products | 114.20 | 128.38 | 129.52 | 112.83 | 99.20 |
Money lending | 22.29 | 14.63 | 10.66 | 1.13 | 0.61 |
Investment in financial instruments | 33.59 | -0.95 | 6.14 | -0.39 | -0.25 |
Total revenue | 170.08 | 142.06 | 146.32 | 113.58 | 99.56 |
Revenue by Segment
| Segment PBT (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese health products | -8.87 | 1.89 | 3.19 | -6.05 | -7.48 |
Money lending | -97.83 | -30.02 | -115.86 | -10.16 | -1.43 |
Investment in financial instruments | 16.91 | -17.75 | -5.68 | -6.41 | 22.80 |
Reportable segment total | -89.79 | -45.88 | -118.34 | -22.62 | 13.89 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese health products PBT margin (%) | -7.8 | 1.5 | 2.5 | -5.4 | -7.5 |
Chinese health products revenue YoY (%) | — | 12.4 | 0.9 | -12.9 | -12.1 |
Chinese health products share of revenue (%) | 67.1 | 90.4 | 88.5 | 99.3 | 99.6 |
Chinese health products goods gross margin (%) | 30.7 | 30.8 | 33.6 | 32.4 | 33.4 |
Money lending revenue YoY (%) | — | -34.4 | -27.1 | -89.4 | -46.0 |
Revenue by Segment (Half-Yearly)
| Segment (HKD Mn) | H1 2025 revenue | H1 2026 revenue | H1 2025 PBT | H1 2026 PBT |
|---|---|---|---|---|
Chinese health products | 50.98 | 47.90 | -4.40 | -3.06 |
Money lending | 0.32 | 0.30 | 0.87 | -2.34 |
Investment in financial instruments | -0.24 | -11.74 | 11.37 | -16.71 |
Total | 51.06 | 36.46 | 7.84 | -22.11 |
Segment assets (HKD Mn)
| Segment assets (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese health products | 84.45 | 92.73 | 88.69 | 75.21 | 62.54 |
Money lending | 167.24 | 137.08 | 17.65 | 8.76 | 6.50 |
Investment in financial instruments | 59.75 | 57.34 | 40.44 | 35.59 | 54.01 |
Consolidated total assets | 314.10 | 287.66 | 149.67 | 122.05 | 125.21 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 170.08 | 142.06 | 146.32 | 113.58 | 99.56 |
Cost of sales (HKD Mn) | 79.09 | 88.79 | 86.02 | 76.23 | 66.10 |
Gross profit (HKD Mn) | 90.99 | 53.27 | 60.29 | 37.35 | 33.46 |
Other income gains and losses net (HKD Mn) | -15.15 | -10.10 | -10.17 | -10.48 | — |
of which FV gain/loss on FVTPL assets (HKD Mn) | -15.30 | -15.33 | -10.34 | -4.19 | 24.61 |
Selling and distribution expenses (HKD Mn) | -31.08 | -28.54 | -27.87 | -29.04 | -28.23 |
General and administrative expenses (HKD Mn) | -33.09 | -38.33 | -37.53 | -26.41 | -21.63 |
ECL impairment on loans net (HKD Mn) | -102.61 | -24.78 | -107.47 | -2.35 | 3.73 |
Operating income EBIT (HKD Mn) | -94.17 | -49.10 | -123.07 | -31.73 | — |
EBITDA (HKD Mn) | -89.97 | -45.80 | -117.45 | -24.56 | — |
Finance costs (HKD Mn) | -6.41 | -7.30 | -8.99 | -8.30 | -13.83 |
Pre-tax income (HKD Mn) | -100.58 | -56.40 | -132.06 | -40.03 | — |
Income tax (HKD Mn) | -2.47 | 2.13 | -2.50 | -0.25 | — |
Net income attributable (HKD Mn) | -103.05 | -54.27 | -134.56 | -40.28 | -2.61 |
EPS basic and diluted (HK cents) | -13.37 | -7.04 | -17.46 | -5.23 | -0.34 |
Dividend per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 23.4 | -16.5 | 3.0 | -22.4 | -12.3 |
Gross margin reported (%) | 53.5 | 37.5 | 41.2 | 32.9 | 33.6 |
Operating margin (%) | -55.4 | -34.6 | -84.1 | -27.9 | — |
EBITDA margin (%) | -52.9 | -32.2 | -80.3 | -21.6 | — |
Net margin (%) | -60.6 | -38.2 | -92.0 | -35.5 | -2.6 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 314.10 | 287.66 | 149.67 | 122.05 | 125.21 |
Cash and equivalents (HKD Mn) | 40.01 | 16.85 | 14.42 | 9.70 | 9.19 |
Inventories (HKD Mn) | 60.71 | 55.12 | 56.02 | 49.77 | 40.11 |
Loan receivables net (HKD Mn) | 138.57 | 134.05 | 17.10 | 8.57 | 6.46 |
FVTPL equity investments (HKD Mn) | 59.30 | 57.31 | 40.42 | 35.59 | 54.01 |
Short-term debt (HKD Mn) | 84.34 | 31.26 | 100.96 | 32.57 | 98.90 |
Long-term debt (HKD Mn) | 0 | 71.04 | 0 | 63.30 | 0 |
Total debt excl leases (HKD Mn) | 84.34 | 102.31 | 100.96 | 95.87 | 98.90 |
Lease liabilities (HKD Mn) | 6.52 | 7.60 | 7.94 | 7.87 | 7.24 |
Net debt excl leases (HKD Mn) | 44.33 | 85.46 | 86.54 | 86.17 | 89.71 |
Total equity (HKD Mn) | 193.06 | 138.65 | 4.40 | -18.38 | -20.99 |
Goodwill and intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital CA minus CL (HKD Mn) | 82.22 | 200.26 | -3.30 | 40.25 | -25.06 |
Balance Sheet and Margin Analysis (%)
| Item (HKD Mn) | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|
Total assets | 125.21 | 72.56 |
Cash and equivalents | 9.19 | 8.55 |
Inventories | 40.11 | 29.91 |
FVTPL investments | 54.01 | 14.14 |
Loan receivables net | 6.46 | 8.62 |
Margin loans from brokers (on demand, 8%–10%) | 15.62 | 2.42 |
Other loan (12%, on demand, secured by subsidiary share charge) | 15.81 | 15.81 |
Convertible loan notes (2024 CBs) | 15.46 | 16.10 |
Bonds payable (2024 straight bonds) | 52.00 | 53.69 |
Total current liabilities | 143.44 | 120.48 |
Net current liabilities | -25.06 | -52.88 |
Net liabilities (capital deficiency) | -20.99 | -50.10 |
Gearing (debt/total assets, company definition) (%) | 79 | 121 |
Current ratio (x) | 0.83 | 0.56 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capex PPE additions (HKD Mn) | 0.36 | 0.63 | 0.19 | 0.26 | — |
Right-of-use asset additions (HKD Mn) | 6.10 | 7.54 | 6.98 | 7.10 | — |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Change in cash (HKD Mn) | — | -23.16 | -2.43 | -4.72 | -0.52 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on average equity (%) | — | -32.7 | -188.1 | — | — |
ROA on average assets (%) | — | -18.0 | -61.5 | -29.6 | -2.1 |
ROIC pre-tax EBIT on closing invested capital (%) | -38.6 | -21.2 | -124.5 | -41.9 | — |
Current ratio (x) | 1.69 | 3.68 | 0.98 | 1.55 | 0.83 |
Debt to equity (x) | 0.44 | 0.74 | 22.95 | — | — |
Interest coverage EBIT to finance costs (x) | -14.7 | -6.7 | -13.7 | -3.8 | — |
Asset turnover (x) | — | 0.47 | 0.67 | 0.84 | 0.81 |
Inventory days on cost of sales | 280.2 | 226.6 | 237.7 | 238.3 | 221.5 |
Receivable days on health-product revenue | 18.2 | 16.5 | 15.6 | 13.1 | 8.8 |
Payable days on cost of sales | 81.2 | 97.7 | 98.7 | 86.5 | 89.4 |
Cash conversion cycle (days) | 217.2 | 145.4 | 154.6 | 164.9 | 140.9 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong | 169.61 | 141.75 | 146.32 | 113.58 | — |
People's Republic of China | 0.47 | 0.31 | 0 | 0 | — |
Total | 170.08 | 142.06 | 146.32 | 113.58 | 99.56 |
Region growth (%)
| Region growth (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Hong Kong YoY (%) | -16.4 | 3.2 | -22.4 |
PRC YoY (%) | -33.9 | -100.0 | — |
Share Price History
| Date | Price / market cap | Source |
|---|---|---|
Jun 2025 | Market cap ≈HK$64.7 M | TipRanks |
Aug 2025 | Market cap ≈HK$104–117 M | TipRanks |
13 Feb 2026 | ≈HK$0.139 (derived from Eternity stake value HK$23.5 M); market cap HK$107.1 M | Simply Wall St |
24 Apr 2026 | HK$0.084 | ET Net |
11 May 2026 | HK$0.056 | ET Net |
13 Jul 2026 | HK$0.056 | ET Net |
27 Jul 2026 | Market cap HK$46.2 M; 1-year -37%; 6-month -64.2% | MarketInOut |
5 Aug 2026 | Placing price HK$0.07 | HKEX announcement |
22 Sep 2026 | 5:1 consolidation; HK$0.056 ≈ HK$0.28 per consolidated share equivalent | Derived |
Share price performance (%) | 1-year | 3-year |
China Healthwise (to 27 Jul 2026) | -37 | — |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap (HKD Mn) | 51.8 | 924.57 M shares × HK$0.056 |
Enterprise value (HKD Mn) | ≈138 |
|
P/E | n/m | Losses |
EV/EBITDA | n/m | Negative/undisclosed EBITDA (vendor EV/EBITDA 8.96x is not reconciled) |
EV/Sales (FY2025) | ≈1.4x | EV / HK$99.6 M |
P/B | n/m | Negative book value |
Capital Instruments
| Instrument | Principal / carrying (HKD Mn) | Coupon | Maturity | Security |
|---|---|---|---|---|
2024 straight bonds | 55.5 principal / 53.69 carrying | 8% (15% effective) | 30 Dec 2026 | 100% share pledge over a subsidiary |
2024 convertible bonds | 16.8 principal / 16.10 carrying | 6% (15% effective); conversion HK$0.088 pre-consolidation | 30 Dec 2026 | Same pledge |
Other loan (finance company) | 15.81 | 12% | Repayable on demand | Share charge over subsidiary; Company guarantee |
Margin loans | 2.42 | 8%–10% | On demand | Listed equities (HK$9.79 M) |
Lease liabilities | 6.58 (4.82 current) | — | Store leases | — |
Total interest-bearing (excl leases) | 88.02 | — | — | — |
Analyst Conclusions
Management guidance
No numerical guidance. Management expects the retail environment to remain "challenging" (weak local consumption, competition, rising costs), the money-lending environment to remain "challenging and difficult", and will continue cost control, channel expansion, portfolio realisation and negotiations with the bondholder and finance company to renew facilities (H1 2026 interim).
Consensus
No sell-side coverage (0 analysts per Simply Wall St). Consensus growth expectations: not available.
Bull case
-
Recovery optionality on a fully written-down loan book. HK$296.7 M of gross stage 3 loans carry zero net value; the Customer I property proposal and ongoing partial repayments mean every recovery dollar is pure upside to equity (FY2025 net ECL reversal was HK$3.73 M).
-
The retail engine is closer to breakeven than headline losses suggest. Goods gross margin is 34% and segment loss was only HK$3.1 M in H1 2026 (a seasonally weak half); with bond interest removed, the operating business could self-fund.
-
Cheap brand. An EV of roughly HK$140 M for a 49-year-old heritage brand with ~HK$100 M revenue (≈1.4x sales) could attract a strategic acquirer, especially if a debt restructuring transfers the brand to a cleaner vehicle.
Bear case
-
Maturity wall. HK$72.3 M of bond principal plus a HK$15.8 M on-demand loan versus ≈HK$19 M of cash (incl. placing) — refinancing, conversion or enforcement is unavoidable before 30 Dec 2026.
-
Secured creditors sit ahead of shareholders on the only valuable asset. Both the bonds and the 12% loan are secured on subsidiary shares; enforcement could leave the listed shell with negligible assets.
-
Structural decline and dilution. Product revenue has fallen ~23% from FY2023 to FY2025 and kept falling in H1 2026, while equity holders have already absorbed a 20% placing and face CB conversion dilution.
Catalysts and monitorables (next 12 months)
-
Outcome of negotiations on the 2024 Bonds before 30 Dec 2026 (extension, conversion, partial repayment or default).
-
Any demand on the HK$15.8 M other loan.
-
Completion of the Customer I asset-for-debt transfer (Guangzhou properties).
-
FY2026 results (expected March 2027): auditor opinion — risk of escalation from emphasis of matter to disclaimer.
-
Winter/Chinese New Year 2027 trading (inventory build funding).
-
Further equity raises after consolidation; resumption of normal trading on counter 0348 after parallel trading.
-
HKEX scrutiny of sufficiency of operations / financial position.
-
Changes in Eternity Investment's stake or support.
Analyst verdict
China Healthwise is not, at present, an operating-company investment case; it is a credit event in waiting attached to a respectable but shrinking heritage retailer. The core business, Nam Pei Hong, is genuinely viable at the gross-profit level — goods margins of 33%–34% have held through a severe Hong Kong consumption downturn, and management has cut G&A by more than 40% since FY2022. But the listed parent spent FY2018–FY2023 deploying capital into an unsecured money-lending book that has proved almost entirely unrecoverable (97% credit-impaired), and into a listed-equity portfolio that has delivered more volatility than return. The result is a capital deficiency of HK$50 million, net current liabilities of HK$53 million, and HK$72 million of secured bond principal maturing on 30 December 2026 against roughly HK$19 million of cash after the August placing.
The FY2025 "near-breakeven" result was an artefact of a HK$24.6 million unrealised equity gain that reversed in the first half of 2026; investors should anchor on the H1 2026 loss of HK$29 million and the 121% debt-to-assets gearing. The August 2026 placing and share consolidation are classic pre-restructuring housekeeping rather than evidence of a turnaround. The decisive variables over the next three months are entirely on the liability side: whether the bondholder extends or converts, and whether secured creditors choose to enforce over the subsidiary that owns the brand.
Equity value therefore depends on negotiated outcomes that are not publicly visible. Upside exists — recoveries on written-off loans and a strategic sale of the Nam Pei Hong brand could each be material relative to a ~HK$50 million market capitalisation — but the probability-weighted outcome skews toward further dilution or loss of control of the operating subsidiary. We would classify the shares as highly speculative.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Background (as disclosed or reported) | Birth year |
|---|---|---|---|---|
Lei Hong Wai (李雄偉) | Chairman, executive director; designated investment director | Chairman since at least 2016/17 | — | 1968 (vendor) |
Cheung Kwok Wai Elton (張國偉) | Vice Chairman, executive director; designated investment director | ED since 28 Oct 2019 | HKICPA (vendor); Eternity-nominated director; over 20 years' experience | 1966 (vendor) |
Leung Alex (梁奕曦) | Executive director | Since at least 2019 | Not detailed in sources reviewed | 1979 (vendor) |
Lo Ming Wan (勞明韵) | Executive director and Company Secretary | Since at least 2019 | Not detailed in sources reviewed | 1986 (vendor) |
Yuan Huixia (袁輝霞) | Executive director | Since at least 2019 | Not detailed in sources reviewed | 1981 (vendor) |
| — | Independent non-executive director; audit and nomination committees | Since 31 Oct 2025 | 20+ years in paper, packaging and printing; INED of Global Mastermind Holdings (8063) and Walnut Capital (905); fee HK$120,000 p.a. | — |
Lai Hok Lim (黎學廉) | INED; audit committee | Since at least 2019 | Not detailed | — |
Tsang Chin Pang (曾展鵬) | INED | — | Not detailed | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
30 Sep 2024 | Tse Chi Keung (ED) resigned | Cost reduction phase |
| — | Wong Tak Chuen (INED, audit committee chair) left; Tsang Chin Pang joined | Board refresh |
27 Jan 2025 | Yang Qiangsheng appointed ED (holds 38.0 M pre-consolidation shares, 4.93% pre-subscription) | Shareholder-director |
| — | Lien Wai Hung (INED) departed | Left the board below required INED numbers |
31 Oct 2025 | Yang Qiangsheng resigned (personal commitments, no disagreement); Fung Wai Ching appointed INED | Re-compliance with Listing Rules on INED numbers |
Directors' Remuneration
| Directors' emoluments (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Total directors' emoluments | 15.61 | 20.16 | 19.06 | 9.09 |
Employee costs excluding directors | 21.85 | 21.58 | 23.36 | 19.88 |
Major Shareholders
| Holder | Shares (pre-consolidation) | % pre-subscription (770.48 M) | % post-subscription (924.57 M, derived) |
|---|---|---|---|
Eternity Investment Limited (0764.HK) | 169,042,824 | 21.94 | 18.28 |
| — | 154,090,000 | — | 16.67 |
Yang Qiangsheng (former ED) | 38,000,000 | 4.93 | 4.11 |
Lei Hong Wai (Chairman) | 18,663,636 | 2.42 | 2.02 |
Public float (31 Dec 2025, per Annual Report 2025) | — | 70.7 | — |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Listing | Positioning vs Nam Pei Hong |
|---|---|---|---|
Beijing Tong Ren Tang Chinese Medicine (3613.HK) | TCM products, tonics, HK retail | HKEX | Far larger, manufacturer-brand owner with proprietary medicines; HK$1,513 M FY2025 revenue |
Eu Yan Sang | TCM, bird's nest, ginseng retail in HK/SE Asia | Private (delisted from SGX) | Dominant HK TCM retail chain; brand and scale advantage |
Wai Yuen Tong Medicine (0897.HK) | TCM products and retail | HKEX | — |
Hung Fook Tong Group (1446.HK) | Herbal drinks and health foods retail | HKEX | — |
Po Sum On, Shiu Fung Hong, and other HK ginseng/dried-seafood houses | Ginseng, dried seafood | Mostly private | Similar heritage merchant model |
Sheung Wan / Des Voeux Road West dried-seafood merchants | Dried seafood, Sum Yung | Private, fragmented | Price competition at wholesale/retail |
Watsons, Mannings (HK health and beauty chains) | Packaged supplements, health foods | Parent-listed (CK Hutchison; Dairy Farm) | Massive footprint in convenience health products |
HKTVmall third-party merchants | Online tonics and supplements | — | Price transparency |
Shenzhen/Mainland retailers and e-commerce (Tmall, JD Health) | All categories | Various | Absorb northbound HK consumer spending |
Hong Kong licensed money lenders (e.g., listed finance subsidiaries) | Money lending | Various | China Healthwise effectively exited new lending |
Peer Comparison FY2025
| Metric | China Healthwise FY2025 | Beijing Tong Ren Tang CM FY2025 |
|---|---|---|
Revenue (HKD Mn) | 99.56 | 1,513 |
Revenue growth (%) | -12.3 | -6.1 |
Gross margin (%) | 33.6 | 61.2 |
Net margin (%) | -2.6 | 26.2 |
R&D intensity (%) | 0 | — |



